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Abstract 
Autoimmune hepatitis (AIH) is a rare cause of chronic liver disease. The backbone of treatment 
is immunosuppressive medication, typically prednisolone as induction therapy and azathio-
prine as a maintenance therapy. Side effects of the long-term use of systemic corticosteroids 
are well known and have led to the use of alternative induction regimens. An attractive alter-
native is budesonide, a nonhalogenated glucocorticosteroid characterized by a high first-pass 
effect in the liver (90%), resulting in a high topical anti-inflammatory activity and a low systemic 
activity. It should be stressed that budesonide is contraindicated in patients with established 
cirrhosis with portal hypertension and portocaval shunting. In this case report, we present the 
first case of adrenal insufficiency following treatment with budesonide for AIH. 
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Introduction 
Side effects of the long-term use of systemic corticosteroids are well known and have led 
to the use of alternative induction regimens. An attractive alternative is budesonide, a 
 Case Rep Gastroenterol 2018;12:597–601 
DOI: 10.1159/000492204 © 2018 The Author(s). Published by S. Karger AG, Basel 
www.karger.com/crg 







nonhalogenated glucocorticosteroid characterized by a high first-pass effect in the liver 
(90%), resulting in a high topical anti-inflammatory activity and a low systemic activity. The 
binding activity of budesonide to the glucocorticosteroid receptor is 15–20 times higher than 
that of prednisolone [1, 2]. Because of 90% inactivation in the liver, the systemic concentra-
tion is low, thus minimizing the effect on the hypothalamic-pituitary-adrenal axis. Due to its 
attractive safety profile, budesonide is now used as an alternative to prednisolone in the treat-
ment of autoimmune hepatitis (AIH) in noncirrhotic patients [3]. It should be stressed that 
budesonide is contraindicated for patients with established cirrhosis with portal hyperten-
sion and portocaval shunting. Portal venous thrombosis has been reported in 2 patients with 
primary biliary cholangitis (PBC) stage IV treated with budesonide and ursodeoxycholic acid 
[4]. In this case report, we present the first case of adrenal insufficiency following treatment 
with budesonide for AIH. 
AIH is a rare chronic liver disease with an estimated prevalence of 15–25 per 100,000. Its 
prevalence may vary according to ethnicity and seems to be increasing. The time of presenta-
tion is bimodal, resulting in a first peak in childhood/teenage years and a second peak be-
tween the 4th and 6th decades. Predominantly women are affected [5].  
Its main features are hypergammaglobulinemia (IgG), typical histological findings on liver 
biopsy (Fig. 1), and response to immunosuppression. If left untreated, this condition can rap-
idly progress to cirrhosis, finally resulting in liver failure and death. Its diagnosis can be chal-
lenging due to the heterogeneity of clinical symptoms and presentation. The spectrum of 
presentation ranges from asymptomatic to acute and severe hepatitis, sometimes resulting in 
liver failure. Most frequently, as seen in two-thirds of cases, patients present with an insidious 
onset without apparent symptoms or vague and general symptoms like fatigue, general feeling 
of illness, lethargy, and anorexia. Because of the quiescent course, one-third of patients will 
already have developed cirrhosis at the time of diagnosis. In about one-quarter of patients, an 
acute hepatitis (true or exacerbation of a chronic form) is seen at presentation. 
A typical but nonspecific finding is a rise in aminotransferases. Cholestatic liver enzymes 
are usually normal or only slightly elevated (only GGT, not ALP). Furthermore, IgG levels are 
typically elevated and autoantibodies are the hallmark of the disease, leading to a subclassifi-
cation into three categories. The first type, AIH 1, is most common (90%). In this type, anti-
neutrophil antibodies (ANA) and/or smooth muscle antibodies or anti-soluble liver anti-
gen/liver pancreas antibodies (anti-SLA/LP) are detected. The second type, AIH 2, accounts 
for about 10% of cases. This subtype is characterized by detection of liver kidney microsomal 
antibodies (anti-LKM1) or anti-LKM3 and/or liver cytosol type 1 antibodies (anti-LC1). AIH 3 
is quite rare and is characterized by the detection of anti-SLA/LP and often Ro-52 antibodies. 
For induction of remission, patients are classically treated with corticosteroids, typically 
high-dose prednisolone. A combination with azathioprine is effective and reduces the corti-
coids’ systemic adverse effects by reducing the dose of corticosteroids needed for remission. 
After achievement of remission, the corticosteroids are gradually tapered. An alternative cor-
ticosteroid is budesonide, characterized by a high first-pass effect in the liver (90%), resulting 
in a high topical anti-inflammatory activity and a low systemic activity, limiting any adverse 
effects. Contraindications are portal hypertension (cirrhosis) or portocaval shunts, because of 
strong systemic adverse effects in these cases. 
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A 39-year-old female without a prior medical history was referred by the general practi-
tioner for complaints of fatigue and elevated liver enzymes (AST/ALT 412/547 U/L, GGT 104 
U/L, AF 81 U/L, and bilirubin 1.5 mg/dL). Her further history was unremarkable. There were 
neither complaints of abdominal pain nor nausea or vomiting. Stool consistency and fre-
quency remained normal. Neither blood in the stool nor discoloration (black or pale) was 
seen. She had no fever, night sweats, or weight loss. No complaints of palpitations, thoracic 
pain, dyspnea, orthopnea, or cough were reported. Semi-recent intake of antibiotics or other 
hepatotoxic drugs was denied by the patient. Her family history regarding liver or autoim-
mune diseases was negative.  
A complete blood analysis was performed and showed no anemia, no thrombopenia, and 
no signs of inflammation. Thyroid function tests seemed normal. Kidney function tests also 
appeared normal; only liver tests were augmented as already stated earlier. Ferritin, copper, 
and ceruloplasmin were normal. Results of initial IgA, IgM, and IgG were not found. Viral se-
rology (CMV, toxoplasmosis, HAV, HBV, HCV, and HEV) remained negative, and immunity 
against EBV was acquired. Also, autoimmune testing (ANA, anti-AMA, anti-LKM, and anti-LC1) 
proved negative. Echography of the abdomen showed no abnormalities. Because neither bio-
chemistry nor echography revealed an evident cause, a liver biopsy was performed. An image 
of chronic hepatitis with mild fibrosis and high inflammatory activity (A3F2) combined with 
infiltration of plasmacytes and eosinophils was observed (Fig. 1). This was suggestive of AIH, 
possibly drug induced. 
Treatment with budesonide 9 mg was started, with good response initially. Upon tapering 
of budesonide after 2 months, the patient showed clinical signs of relapse. Therefore, azathi-
oprine was added. Hereafter, transaminases returned to normal levels. However, the patient 
was still not feeling well, with persistent complaints of fatigue. Treatment with azathioprine 
was stopped because concerns arose that the fatigue might be a side effect of this treatment. 
Three months later, the fatigue had increased. Furthermore, the patient reported, for the first 
time, concentration disorders, muscle weakness, weight loss, orthostatism, and amenorrhea. 
At this time, endocrinologic testing was performed. We saw a normal thyroid gland function, 
but early-morning plasma cortisol values were significantly decreased (18.8 µg/L; reference: 
67–226), which was concordant with a low urinary cortisol level (12.0 μg/24 h urine; refer-
ence 36–137) and decreased ACTH (<5.0 ng/L). 
Budesonide treatment was stopped, and adrenal substitution with hydrocortisone (20  
mg – 5 mg – 10 g) was started. After 2 months of treatment, an improved morning cortisol 
level (69.3 µg/L) was observed. Hydrocortisone was gradually tapered. However, ACTH re-
mained low (<5.0 ng/L). Thus, a Synacthen test was performed to investigate the reactivity of 
the adrenal gland. Cortisol levels at 30, 60, and 90 min were 66.1, 73.9, and 72.8 µg/L, respec-
tively, showing insufficient adrenal recuperation at that moment. Hydrocortisone treatment 
needed to be continued and was, later on, gradually tapered. Liver function tests remained 
normal. 
Discussion 
Only a few cases of adrenal insufficiency caused by budesonide have been reported. These 
reports involved patients treated with budesonide for Crohn’s disease or asthma [6]. Pharma-
cokinetic and pharmacodynamic analysis of budesonide 9 mg treatment for 3 weeks in 19 
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patients with PBC showed significantly lower morning plasma cortisol and urinary cortisol 
levels in late-stage PBC (cirrhosis) compared with early-stage PBC [4]. This underlines the 
importance of normal liver function to limit the systemic effects of budesonide. A decreased 
liver function presents as lowered albumin, elevated bilirubin, and lowered prothrombin time 
and results in a higher systemic budesonide concentration. In the presence of portal hyper-
tension and portocaval shunting, as seen in cirrhosis, the systemic concentration of 
budesonide is even higher. 
The patient in this case, however, had a normal liver function without signs of cirrhosis 
on liver biopsy. Only mild fibrosis was reported. Furthermore, there were no signs of portal 
hypertension or shunting. No specific medications affecting the hypothalamic-pituitary- 
adrenal axis, excluding budesonide, were ingested during this period, nor did the patient take 
any medications which influenced CYP3A4, needed for metabolism of budesonide. The patient 
only intermittently used vaginal creme containing isoconazole (Travocort®). Ketoconazoles 
inhibit CYP3A4, but the systemic effects of local use are unlikely to be significant. 
We conclude that this patient with AIH developed iatrogenic adrenal insufficiency follow-
ing oral budesonide treatment. Although it is an attractive treatment strategy for AIH patients 
without cirrhosis, caution is advised for persistent, vague symptoms which could reflect ad-
renal insufficiency. Simultaneous intake of other drugs affecting CYP3A4 should be taken into 
account and should better be avoided. 
Statement of Ethics 
The authors have no ethical conflicts to disclose. 
Disclosure Statement 
There are no conflicts of interest. 
References 
1 Möllmann HW, Barth J, Hochhaus G, Möllmann A, Derendorf H, Tromm A. Principles of topical vs systemic 
corticoid treatment in inflammatory bowel disease. In: Möllmann HW, May B, editors. Glucocorticoid 
therapy in chronic inflammatory bowel disease. From basic principles to rational therapy. Dordrecht: 
Kluwer Academic Publishers; 1996. p. 42–60. 
2 Möllman HW, Hochhaus G, Tromm A, Froehlich P, Möllmann AC, Krieg M, et al. Pharmacokinetics and 
pharmacodynamics of Budesonide-pH-modified release capsules. In: Möllmann HW, May B, editors. 
Glucocorticoid therapy in chronic inflammatory bowel disease. From basic principles to rational therapy. 
Dordrecht: Kluwer Academic Publishers; 1996. p. 107–20. 
3 Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, et al.; European AIH-BUC-Study Group. 
Budesonide induces remission more effectively than prednisone in a controlled trial of patients with 
autoimmune hepatitis. Gastroenterology. 2010 Oct;139(4):1198–206. 
4 Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and 
pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology. 2003 
Jul;38(1):196–202. 
5 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: autoimmune hepatitis.  
J Hepatol. 2015 Oct;63(4):971–1004. 
6 Berkelhammer C, Trabolsi M, Andrejic J, Yasmeen T. Severe adrenal insufficiency complicating budesonide 
therapy for Crohn’s disease. Inflamm Bowel Dis. 2011 Apr;17(4):1053–4. 
 
 
 Case Rep Gastroenterol 2018;12:597–601 
DOI: 10.1159/000492204 © 2018 The Author(s). Published by S. Karger AG, Basel 
www.karger.com/crg 











Fig. 1. Liver biopsy showed a chronic hepatitis-like injury with an intense mixed portal and periportal in-
flammation composed mainly of lymphocytes and macrophages, accompanied by some eosinophils. There 
was no profusion of plasma cells. Interface hepatitis was marked and was associated with periportal fibro-
sis. There was also lobular inflammation with spotty necrosis and apoptosis. The short arrows point to 
hepatic rosette formation; the long arrow points to a focus of emperipolesis. Hematoxylin-eosin stain. Mag-
nification, ×250. 
 
